公开(公告)号：US11820981B2

公开(公告)日：2023-11-21

申请号：US16333586

申请日：2017-09-14

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Walter Hunziker ,  Jianliang Xu ,  Jiong-Wei Wang ,  P. Jaya Kausalya

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K35/761 ,  A61K38/17 ,  A61K38/18 ,  A61P9/10 ,  A61K31/713 ,  A61K31/7088

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K35/761 ,  A61K38/1709 ,  A61K38/1825 ,  A61K38/1866 ,  A61K38/1883 ,  A61P9/10 ,  A61K31/7088 ,  A61K38/1808 ,  A61K38/1841 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/341 ,  C12N2310/531

Abstract: The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject comprising the step of administering to the subject a Tjp1 inhibitor, wherein administration of said Tjp1 inhibitor promotes cardiomyocyte proliferation. The invention further includes use of Tjp1 inhibitor in the manufacture of a medicament for a heart disease, a patch, and a nucleic acid encoding a Tjp1 inhibitor. In a particular embodiment, the Tjp1 inhibitor is a nucleic acid, i.e. an siRNA or shRNA of Tjp1. The invention also includes administration of said Tjp1 inhibitor in combination with Neuregulin-1 (NRG1), Fibroblast growth factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst1) and wherein said inhibitor is delivered in an adeno-associated virus of serotype 9 (AAV 9).

公开(公告)号：US20250122506A1

公开(公告)日：2025-04-17

申请号：US18687385

申请日：2022-09-16

Applicant: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH

Inventor： Jianliang Xu ,  Walter Hunziker ,  Jaya Kausalya P

IPC: C12N15/113 ,  A61P35/00

Abstract: Disclosed is a method for treating a liver disease in a subject comprising administering a Tjp1 inhibitor to the subject. Also disclosed are a kit and a nucleic acid encoding a Tjp1 inhibitor.